Merck KGaA Sponsored ADR (MKKGY)
OTHER OTC:MKKGY
Top Page
Merck KGaA Sponsored ADR
(OTC:MKKGY)
Select Model
Select Model
Rating:59Neutral
Price Target:
$29.00
▼(-2.68% Downside)
Action:DowngradedDate:03/14/26
The score is driven primarily by solid but weakening fundamentals (good margins and free cash flow, but choppy revenue and a 2025 profit step-down with rising debt) and a bearish technical setup (below major moving averages and negative MACD). Valuation is a headwind due to a high P/E, while the earnings call adds a mixed outlook with resilient execution but constrained 2026 guidance amid FX and Mavenclad exclusivity loss.
Positive Factors
Diversified, recurring revenue streams
Merck KGaA’s three-segment model (Life Science, Healthcare, Electronics) creates multiple, partly uncorrelated revenue streams and recurring consumables demand in bioprocessing and labs. This structural diversification smooths cash flow cycles and reduces reliance on any single product or market over months to years.
Negative Factors
Choppy revenue and profit step-down
Intermittent top-line performance and a recent step-down in net income reduce visibility and make margin maintenance harder over time. Without stable organic revenue growth, sustaining mid‑teens margins and funding ongoing R&D and capex becomes more challenging, increasing execution risk in the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Diversified, recurring revenue streams
Merck KGaA’s three-segment model (Life Science, Healthcare, Electronics) creates multiple, partly uncorrelated revenue streams and recurring consumables demand in bioprocessing and labs. This structural diversification smooths cash flow cycles and reduces reliance on any single product or market over months to years.
Read all positive factors
Merck KGaA Sponsored ADR (MKKGY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$57.93B
Dividend Yield1.77%
Average Volume (3M)19.41K
Price to Earnings (P/E)42.0
Beta (1Y)0.64
Revenue Growth3.47%
EPS Growth12.07%
CountryUS
Employees59,020
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.43
Shares Outstanding646,211,240
10 Day Avg. Volume0
30 Day Avg. Volume19,407
Financial Highlights & Ratios
PEG Ratio-2.05
Price to Book (P/B)1.86
Price to Sales (P/S)2.62
P/FCF Ratio23.53
Enterprise Value/Market Cap1.03
Enterprise Value/Revenue2.85
Enterprise Value/Gross Profit4.86
Enterprise Value/Ebitda9.58
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.78
Revenue Forecast (FY)$24.10B
Merck KGaA Sponsored ADR Business Overview & Revenue Model
Company Description
Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company's Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and p...
How the Company Makes Money
Merck KGaA makes money primarily by selling products and services across its three operating segments: (1) Life Science: Revenue is generated from selling laboratory consumables and equipment, chemicals and reagents, and bioprocessing products (su...
Merck KGaA Sponsored ADR Earnings Call Summary
Earnings Call Date:Mar 05, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 14, 2026
Earnings Call Sentiment Neutral
The call presented a mixed but resilient picture: Merck delivered on 2025 guidance, achieved organic EBITDA growth, and showed sector-level recoveries (notably Life Science and semiconductor materials) and strategic progress through M&A and site investments. However, meaningful headwinds remain — significant foreign exchange pressures, the imminent U.S. loss of Mavenclad exclusivity, near-term weakness in the Electronics DS&S business, and regulatory/portfolio uncertainties. Management’s proactive strategic moves and solid cash generation balance these risks, leaving the company positioned for medium-term growth but with clear short-term challenges.Positive Updates
Delivered on Full-Year Guidance
Merck delivered on its 2025 guidance with group net sales around stable at EUR 21.1 billion and group EBITDA pre of EUR 6.1 billion, corresponding to a margin of 28.9%.
Negative Updates
Material Foreign Exchange Headwinds
Strong negative FX effects (~4% headwind on net sales) weighed on 2025 net sales and EBITDA pre; management expects continued negative and volatile FX for 2026 with a disproportionate Q1 FX headwind.
Read all updates
Q4-2025 Updates
Positive
Negative
Delivered on Full-Year Guidance
Merck delivered on its 2025 guidance with group net sales around stable at EUR 21.1 billion and group EBITDA pre of EUR 6.1 billion, corresponding to a margin of 28.9%.
Read all positive updates
Company Guidance
Merck guided for 2026 to group net sales of EUR 20.0–21.1 billion (organic sales -1% to +2%) and group EBITDA pre of EUR 5.5–6.0 billion, based on three key assumptions: portfolio effects from the SpringWorks acquisition and Surface Solutions divestment (portfolio items to show effects in H1 and contribute organically in H2), no U.S. Mavenclad sales from March 2026 (Mavenclad was ~EUR 1.2 billion in 2025, roughly 50% in the U.S.), and continued negative and volatile FX (with a disproportionate Q1 headwind). Sector guidance: Life Science is expected to deliver mid-single-digit organic growth, Healthcare faces a challenging year with life‑cycle pressure on key brands (notably Mavenclad) but growth in CM&E, fertility and rare‑diseases (rare diseases turning organic in H2), and Electronics should see continued strong growth in semiconductor materials while DS&S stabilizes.Merck KGaA Sponsored ADR Financial Statement Overview
Summary
Income Statement
68
Positive
Balance Sheet
72
Positive
Cash Flow
63
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 20.27B | 21.16B | 20.99B | 22.23B | 19.69B |
| Gross Profit | 11.42B | 12.48B | 12.39B | 13.71B | 12.34B |
| EBITDA | 5.71B | 5.96B | 5.68B | 6.28B | 5.88B |
| Net Income | 2.51B | 2.78B | 2.82B | 3.33B | 3.06B |
Balance Sheet | |||||
| Total Assets | 52.08B | 51.57B | 48.49B | 48.53B | 45.36B |
| Cash, Cash Equivalents and Short-Term Investments | 2.74B | 2.71B | 2.41B | 1.64B | 1.62B |
| Total Debt | 11.96B | 10.27B | 9.86B | 10.40B | 10.77B |
| Total Liabilities | 23.43B | 21.58B | 21.74B | 22.52B | 23.95B |
| Stockholders Equity | 28.58B | 29.91B | 26.68B | 25.93B | 21.34B |
Cash Flow | |||||
| Free Cash Flow | 2.26B | 2.40B | 1.76B | 2.45B | 3.19B |
| Operating Cash Flow | 3.78B | 4.59B | 3.78B | 4.26B | 4.62B |
| Investing Cash Flow | -4.09B | -3.05B | -1.89B | -2.74B | -1.58B |
| Financing Cash Flow | 603.21M | -985.00M | -1.73B | -1.55B | -2.50B |
Merck KGaA Sponsored ADR Technical Analysis
Positive
29.80
Price Trends
27.15
Positive
27.79
Negative
26.91
Positive
Market Momentum
-0.04
Negative
61.73
Neutral
96.99
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MKKGY, the sentiment is Positive. The current price of 29.8 is above the 20-day moving average (MA) of 25.19, above the 50-day MA of 27.15, and above the 200-day MA of 26.91, indicating a bullish trend. The MACD of -0.04 indicates Negative momentum. The RSI at 61.73 is Neutral, neither overbought nor oversold. The STOCH value of 96.99 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MKKGY.
Merck KGaA Sponsored ADR Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | $11.06B | 21.72 | 16.00% | 0.64% | 10.63% | 6.35% | |
66 Neutral | $43.57B | 20.62 | 6.43% | 1.74% | 0.58% | 45.74% | |
61 Neutral | $36.16B | 25.43 | 20.09% | ― | -0.25% | ― | |
61 Neutral | $56.21B | 18.30 | 1.58% | 3.86% | -1.98% | -86.20% | |
59 Neutral | $57.93B | 41.98 | 9.02% | 1.77% | 3.47% | 12.07% | |
56 Neutral | $15.92B | -4.15 | -22.99% | 3.99% | -6.40% | -320.23% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
MKKGY
Merck KGaA Sponsored ADR
27.53
0.91
3.40%
RDY
Dr Reddy's Laboratories
13.13
-0.12
-0.93%
VTRS
Viatris
13.91
6.76
94.65%
TEVA
Teva Pharmaceutical
31.77
18.17
133.60%
TAK
Takeda Pharmaceutical Company
17.85
3.31
22.76%
HLN
Haleon PLC Sponsored ADR
9.70
-0.12
-1.18%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.